Cargando…
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a m...
Autores principales: | Schäfer, Alexandra, Muecksch, Frauke, Lorenzi, Julio C. C., Leist, Sarah R., Cipolla, Melissa, Bournazos, Stylianos, Schmidt, Fabian, Gazumyan, Anna, Baric, Ralph S., Robbiani, Davide F., Hatziioannou, Theodora, Ravetch, Jeffrey V., Bieniasz, Paul D., Nussenzweig, Michel C., Sheahan, Timothy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523108/ https://www.ncbi.nlm.nih.gov/pubmed/32995782 http://dx.doi.org/10.1101/2020.09.15.298067 |
Ejemplares similares
-
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
por: Schäfer, Alexandra, et al.
Publicado: (2020) -
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
por: Zhang, Fengwen, et al.
Publicado: (2023) -
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
por: Schmidt, Fabian, et al.
Publicado: (2020) -
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
por: Schmidt, Fabian, et al.
Publicado: (2020) -
Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
por: Wang, Zijun, et al.
Publicado: (2020)